dades infecciosas. Los antimicrobianos eficaces son imprescindibles para las medidas preventivas y curativas, para proteger a los pacientes frente a enfermedades potencialmente mortales y para garantizar que se puedan llevar a cabo procedimientos complejos, como la cirugía y la quimioterapia, con e...scasos riesgos. Sin embargo, el mal uso y el abuso sistemático de estos fármacos en la medicina y la producción de alimentos han puesto en riesgo a todas las naciones. Hay pocos productos de recambio en fase de investigación y desarrollo. Sin medidas armonizadas e inmediatas a escala mundial avanzamos hacia una era posantibiótica en la que infecciones comunes podrían volver a ser mortales.
more
The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatment of TB meningitis, the use of bedaquiline and delama...nid in young children with multidrug- and rifampicin-resistant TB and decentralized and family-centred, integrated models of care for TB case detection and prevention in children and adolescents.
more
Laboratory Biossafety Manual
En 2015, 26 % des décès de 5,9 millions d'enfants de moins de cinq ans auraient pu être évités si les facteurs de risque
environnementaux avaient été pris en compte – cette possibilité manquée de sauver des vies est révoltante. La période prénatale
et de la petite enfance constitue u...ne source de vulnérabilité particulière, les menaces environnementales pouvant provoquer une
naissance prématurée et d'autres complications, et accroître le risque de maladies chroniques, et notamment de troubles respiratoires, de maladie cardiovasculaire et de cancer. L'environnement est donc un facteur majeur de la santé des enfants et offre d'importantes possibilités d'amélioration dont les effets se manifestent dans toutes les régions du monde.
more
During the first two years of the project (2019–2020), through a ‘One Health’ approach, comprehensive engagement was established with AMR coordinating committees, WHO regional and country offices and SORT IT partners in Asia, Africa, Europe and the Americas. Thirty-seven research studies were ...launched to inform AMR action plans in target country studies – local research, for local solutions, with local ownership.
more
Ces directives sont destinées à ceux qui sont responsables de l'élaboration des politiques et de la supervision des pratiques professionnelles des infirmières, des sages-femmes et d'autres prestataires de la santé. Elles veulent également promouvoir le combat contre la "médicalisation" de ces... pratiques et apporter un soutien aux infirmiers, sages-femmes et tout autre personnels de santé afin qu'ils observent les directives de l'OMS préconisant de ne pas suturer une infibulation ouverte.
more
Policy Brief November 2021 Available in English, Spanish and Portuguese
The COVID-19 pandemic has fueled the ongoing antimicrobial resistance (AMR) global crisis due to the increase in the use of antibiotics to treat COVID-19 patients, disruptions to infection prevention and control practices in o...verwhelmed health systems, and diversion of human and financial resources away from monitoring and responding to AMR threats. Moreover, AMR is likely to have caused more COVID-19 deaths, as secondary bacterial infections can worsen the outcome of severe and critical COVID-19 illness. Therefore, it is more urgent than ever to prioritize efforts towards AMR containment and support countries to improve the detection, characterization and rapid response to emerging AMR.
more
The Region of the Americas comprises 46 countries and territories and Brazil and Peru are among the WHO high- TB burden
countries. T o illustrate the recent increase in TB incidence in the region, we selected 12 countries from Latin America (Argentina,
Brazil, Chile, Colombia, Ecuador, El Salvador..., Mexico, Panama, Paraguay, Peru, Uruguay and Venezuela), which account for approximately 80% of the total estimated TB cases in the region.
more
Interim rapid response guidance, 10 June 2022.
It includes considerations for certain populations such as patients with mild disease with considerations for community care, patients with moderate to severe disease, sexually active persons, pregnant or breastfeeding women, children and young persons.... The guidance also addresses considerations for clinical management such as the use of therapeutics, nutritional support, mental health services, and post-infection follow-up.
The document provides guidance for clinicians, health facility managers, health workers and infection prevention and control practitioners including but not limited to those working in primary care clinics, sexual health clinics, emergency departments, infectious diseases clinics, genitourinary clinics, dermatology clinics, maternity services, paediatrics, obstetrics and gynaecology and acute care facilities that provide care for patients with suspected or confirmed monkeypox
more
Severe bacterial infections are a leading cause of morbidity and mortality among people with advanced HIV disease, after tuberculosis and cryptococcal disease. For countries to reach the end-AIDS targets for 2030, there is a need to establish a roadmap for managing severe bacterial infections and re...duce mortality. The purpose of the meeting was to
Review the current research and implementation data on the use of prophylactic antibiotics (specifically azithromycin/macrolides) as part of the AHD package of care; To review options for preventing SBIs that are in line with goals of reducing AMR; Present the current evidence on diagnostics for SBI; Discuss research gaps and implementation challenges.
more
This document provides interim guidance to countries on testing considerations and strategies for suspect cases of severe acute hepatitis of unknown aetiology in children. It is primarily intended for clinical, programmatic, laboratory and diagnostic stakeholders across Member States and national pu...blic health authorities involved in the identification and investigation of cases of severe acute hepatitis in children.
This document is part of a package of guidance for this event, which includes suggested minimum reporting variables and a clinical Case Report Form support Member States with case investigation and reporting.
more
Updated 2 June 2022.#
This entry contains the Status Report of WHO Collaborating Centres in the Americas by Country and a new document with information of Collaborating Centres by Outcome of the Strategic Plan of the Pan American Health Organization 2020‑2025.
This report presents an analysis of antibacterial agents in preclinical (third annual review) and clinical (fifth annual review) development. The analysis covers traditional (direct-acting small molecules) and non-traditional antibacterial agents in development worldwide. It evaluates to what extent... the present pipeline addresses infections caused by WHO Priority Pathogens, Mycobacterium tuberculosis and Clostridioides difficile. The report also provides an assessment of the traditional agents with respect to whether they meet a set of predefined criteria for innovation, namely absence of known cross-resistance, new target, mode of action and/or class. It also includes an overview of the agents that obtained authorization since 1 July 2017.
more
2nd edition. These guidelines include several notable changes from the first edition. For cutaneous leishmaniasis, ketoconazole has been removed from the list of treatment options; the number of Leishmania species for which there is strong evidence for the efficacy of miltefosine has increased from ...two to four; and the recommendation for intralesional antimonials is now strong. For mucosal leishmaniasis there is now a strong recommendation for use of pentavalent antimonials with or without oral pentoxifylline. For visceral leishmaniasis, the strong recommendations for use of pentavalent antimonials and amphotericin B deoxycholate are now conditional.
more
Interim rapid response guidance, 10 June 2022.
It includes considerations for certain populations such as patients with mild disease with considerations for community care, patients with moderate to severe disease, sexually active persons, pregnant or breastfeeding women, children and young persons.... The guidance also addresses considerations for clinical management such as the use of therapeutics, nutritional support, mental health services, and post-infection follow-up.
The document provides guidance for clinicians, health facility managers, health workers and infection prevention and control practitioners including but not limited to those working in primary care clinics, sexual health clinics, emergency departments, infectious diseases clinics, genitourinary clinics, dermatology clinics, maternity services, paediatrics, obstetrics and gynaecology and acute care facilities that provide care for patients with suspected or confirmed monkeypox
more
first issued 18 August 2022